The Children's Hospital of Philadelphia

University of Michigan

Microsoft Technology Licensing, LLC

University of Miami

Other

Drexel University

University of Pennsylvania

Robert J Levy

Ivan Alferiev

Ilia Fishbein

Michael Chorny

Maxim Mazeev

Stanley Stachelek

Darryl Williams

Amnon Sintov

Sundaram Ramani

Eckhard R Podack

Narendra Vyavahare

Zeke Koch

Ori Amiga

Jason William Fuller

Vinod D Labhasetwar

Benjamin B Yellen

Brian David Cross

Jan H Karachale

Daniel John Wigdor

Gennady Friedman

Kevin Alan Kennedy

Steven A Goldstein

Bryan Beatty

Doug Kramer

Paul Armistead Hoover

Sarah Graham Williams

Sarat Chandra Subramaniam

Vladimir R Muzykantov

Peter I Lelkes

John Guido Atkins Weiss

Mengyan Li

Jeffrey F Bonadio

Dennis E Discher

Vadim Deyev

Boris Polyak

Scot Daniel Anderson

Ardan Arac

Hagit Cohen

Zachary G Forbes

Kenneth A Barbee

Carlos Pessoa

Joyce Wu

Russell Composto

John Weiss

Elizabeth Hood

Anat Perets

Mitchell Waite

Danielle Hirsch

Michael D Cronin

Pimporn Uttayarat

Luis Eduardo Cabrera Cordon

Ian Middleton

Cunxian Song

Denise Y Burton

Peter L Jones

Jeanne M Connolly

Quanyi Li

Abigail Christian

Scott Baldwin

Timothy Crombleholme

Ravi Joshi

Eyal Lerner

Vinod Labhasetwar

Eckhard Podack

Richard Tsai

Ilia Fischbein

Stanley J Stachelek

This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, e.g., to treat disease caused by asthma and chronic inflammation, such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein can inhibit CD8 T cell-mediated cellular immune responses and can, for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines. TNFR25 specific immunotoxins disclosed herein are also capable of increasing the effectiveness of a chemotherapeutic regimen by depleting a cancer patient of naturally occurring immunosuppressive cells.

Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins

A unified mechanism for storing device, application, and service state, as well as a rich notification brokerage architecture includes a notification broker. Clients register with the notification broker to receive notifications for changes to state properties. When a registered state property changes, a notification broker determines which clients to notify of the state change and provides the client with a notification regarding the change. Clients may be notified whenever a state changes, when a state change meets a predetermined condition, or based on a schedule. An application may also be launched in response to a state change. An application programming interface (API) is provided that provides a unified way of accessing state change information across different components within the device.

Flexible architecture for notifying applications of state changes

Oxidation resistant bioprosthetic tissues and oxidation resistant bioprosthetic heart valve leaflets are described. Also provided are methods for preparing the oxidation resistant bioprosthetic tissues and bioprosthetic heart valve leaflets, and methods for preventing oxidative degeneration in bioprosthetic tissues, including immobilizing covalently an effective amount of an antioxidant to the bioprosthetic tissue.

Oxidation resistant bioprosthetic tissues and preparation thereof

A water-soluble photo-activatable polymer including: a photo-activatable group adapted to be activated by an irradiation source and to form a covalent bond between the water-soluble photo-activatable polymer and a matrix having at least one carbon; a reactive group adapted to covalently react with a biomaterial for subsequent delivery of the biomaterial to a cell; a hydrophilic group; and a polymer precursor. A composition including a monomolecular layer of the water-soluble photo-activatable polymer and a matrix having at least one carbon, wherein the monomolecular layer is covalently attached to the matrix by a covalent bond between the photo-activatable group and the at least one carbon. The composition further includes a biomaterial having a plurality of active groups, wherein the biomaterial is covalently attached to the monomolecular layer by covalent bonding between the active groups and reactive groups. Also provided is a method for delivery of a biomaterial to a cell.

Photochemical activation of surfaces for attaching biomaterial

The aggregation of multiple inputs in a touch-sensitive input device is disclosed. For example, one disclosed embodiment comprises receiving multiple inputs related to a virtual object, aggregating the inputs into an aggregated output, and providing the aggregated output to an application that controls the virtual object.

Input aggregation for a multi-touch device

A control system is disclosed that is configurable (e.g., by a programmer) so as to enable input from multiple sources to capture to multiple controls. Also or alternatively, the system is configurable so as to enable input from multiple sources to capture to a single control. The system also provides a consistent and extendable scheme for filtering out conflicting events for individual controls. In one embodiment, this means that the system is configurable (e.g., based on the programmer's asserted preferences) so as to enable a selective determination as to whether additional inputs can be captured for a given control.

Selective enabling of multi-input controls

A therapeutic particle comprises a particle comprising one or more therapeutic agents and one or more fibrin-avid peptide variants attached to the surface of the particle. A method for magnetically targeting a therapeutic agent toward a device in a subject, such as a temporarily introduced magnetizable catheter or an implanted stent, comprises administering the therapeutic particles to the subject and generating a magnetic field, which targets the magnetic particles toward the device. The affinity peptide-modified therapeutic particles may comprise an effective amount of an anti-proliferative agent, such as paclitaxel, to inhibit or prevent in-stent restenosis.

Affinity peptide-modified particles and targeted drug delivery methods

A prodrug according to formula (I) wherein Ris a residue of a drug, said drug having a hydroxyl group by which the COORgroup is formed; Z is O or NH; m is 0 or 1; and Ris an organic moiety comprising a lipophilic group or a residue of a polymer, provided that Z is 0 if the polymer is carboxymethyl dextran. A system includes a plurality of magnetic nanoparticles including a prodrug as described above, a stent and a source of uniform magnetic field capable of producing temporary magnetization of the stent and/or the magnetic nanoparticles. A method of treating a medical condition with a drug includes administering to a patient in need of the drug a prodrug as described above, the prodrug being capable of releasing the drug in the patient after the administration step.

Hydrolytically releasable prodrugs for sustained release nanoparticle formulations

The present invention relates to a hybrid graft and methods of generating the hybrid graft. The hybrid graft comprises an exterior surface and a luminal surface. The luminal surface comprises a micropattern of grooves to which cells adhere and orient along. The exterior surface comprises electrospun microfibers wherein the microfibers provide mechanical properties to the graft. The hybrid graft is capable supporting endothelial cell attachment, endothelial cell alignment, cell proliferation, and maintaining their in vivo function. The graft of the invention can recapitulate the in vivo morphology and function of natural vascular endothelium.

Small diameter vascular graft produced by a hybrid method

Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles.

Uniform field magnetization and targeting of therapeutic formulations

A treatment system includes a magnetic targeting catheter and a plurality of MNP. The MNP may include one or more magnetic field-responsive agents and one or more therapeutic agents. The catheter may include an inner shaft having at least one lumen and a fluid delivery balloon adapted to administer a fluid from the inner shaft into a space surrounding the catheter. An expandable mesh formed of a magnetizable material may surround the fluid delivery balloon. The catheter may further include one or more occlusion balloons for controlling blood flow through a vessel in which the catheter is placed. A method of treating a medical condition may include advancing a magnetic targeting catheter to a site, deploying an expandable mesh connected to the catheter, applying a magnetic field to the mesh and depositing a plurality of MNP or cells loaded with MNP near the mesh.

Magnetic targeting device, system and method

Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Therapeutic particles can comprise antioxidant enzymes, and can be targeted to cells to protect the cells from oxidative damage.

Compositions and methods utilizing immunomodulating agents can either stimulate or indirectly augment the immune system or have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used to treat disease caused by asthma and chronic inflammation such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein are capable of inhibiting CD8 T cell-mediated cellular immune responses and can for example, mitigate organ or tissue rejection following a tissue transplantation.

Growing community of inventors

Merion Station, PA, United States of America

Robert J Levy